Back to Search
MARTIN MARKOWITZ, MD
MD
Infectious Disease Physician
NPI: 1790987030Individual
Specialties, Licenses & Credentials
Infectious Disease PhysicianPrimary
Internal Medicine — Infectious Disease
Code: 207RI0200X
145826(NY)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
PMID 24720702·N Engl J Med·2014
3-trial
Telbivudine improves renal function in patients with chronic hepatitis B.
PMID 24067879·Gastroenterology·2014
3-trial
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
PMID 24209977·Lancet·2014
3-trial
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
PMID 19648823·J Acquir Immune Defic Syndr·2009
2-rct
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
PMID 17721395·J Acquir Immune Defic Syndr·2007
4-observational
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
PMID 17554217·J Acquir Immune Defic Syndr·2007
3-trial
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
PMID 17133211·J Acquir Immune Defic Syndr·2006
4-observational
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
PMID 15980684·J Acquir Immune Defic Syndr·2005
3-trial
A randomized trial of calcium supplementation for childhood lead poisoning.
PMID 14702492·Pediatrics·2004
3-trial
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.
PMID 12663814·J Virol·2003
8-other
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.
PMID 12195350·J Infect Dis·2002
3-trial
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.
PMID 19487424·J Exp Med·2009
8-other
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.
PMID 19582166·PLoS Med·2009
8-other
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
PMID 19651917·Antimicrob Agents Chemother·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 455 1ST AVE, 7TH FLOOR AARON DIAMOND AIDS RESEARCH CENTER
NEW YORK, NY 10016 - Phone
- (212) 448-5020
Quick Facts
- NPI
- 1790987030
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile